Protease nexin-1 (PN1) is a specific and extremely efficient inhibitor of thrombin.
INTRODUCTION
Protease nexin-1 (PN1, also known as glia-derived nexin and SERPINE2) is a member of the serine protease inhibitor (serpin) family 1, 2 . The mechanism by which serpins inhibit proteases involves a major conformational change concomitant with a distortion of the target protease 3 . This mechanism is irreversible with a high degree of complexity, and was naturally selected over other inhibitor families to regulate the tightly controlled processes in human such as hemostasis and fibrinolysis 4 . Most of the proteases involved in blood coagulation are regulated by serpins 5 . Thrombin is the central enzyme in blood coagulation and is of vital importance to human life 6 . All endogenous inhibitors of thrombin are serpins, namely: antithrombin (AT), for inhibiting the majority of thrombin generated during blood coagulation; heparin cofactor II (HCII), which inhibits thrombin in a dermatan-sulfate dependent manner in the arterial vasculature; protein C inhibitor (PCI), which inhibits thrombin in complex with thrombomodulin (TM); and PN1, which inhibits thrombin at the vessel wall and platelet surface. Despite the conserved protein fold and inhibition mechanism, these serpins have evolved radically different regulatory mechanisms with regards to thrombin recognition 5, 7 . AT circulates at a high concentration in a low-activity state, and is of principal importance for inhibiting luminal thrombin. In the microvasculature, AT associates with heparan sulfate with high affinity to increase its rate of thrombin inhibition. HCII also circulates at a high concentration, but in a completely inert state until it associates loosely to dermatan sulfate. PCI circulates at a low concentration in an active state, but is a poor inhibitor of thrombin in the absence of cofactors such as TM. PN1, on the other hand, is found exclusively bound to glycosaminoglycans (GAGs) on various cell surfaces, and is not found in the ) exceeds the diffusion limit for a normal bimolecular reaction 8 . The extremely high rate of inhibition ensures that any thrombin that reaches the surface of a cell on which PN1 resides will be inhibited before thrombin can effect any other activity, until, that is, the PN1 is exhausted. PN1
has therefore been proposed to play a protective role against the proliferative effects of thrombin on smooth muscle cells 9 , and to set the 'threshold' for platelet activation by thrombin 10 . Recent studies have demonstrated an important antithrombotic effect of platelet PN1 in vitro and in vivo 11 .
We have previously reported on the structural basis of thrombin recognition by serpins AT 12 , HCII 13 and PCI
14
.
Here we complete the structural study of thrombin recognition by serpins by solving the crystal structures of the PN1-heparin complex and of PN1 in complex with S195A thrombin. We show that native PN1 has a typical serpin fold with a highly positively charged helix D harboring the heparin binding residues, and an additional basic surface on and around the reactive centre loop (RCL) which facilitates the formation of the initial encounter complex with thrombin. Two distinct complexes were found in the crystal of PN1 and thrombin: one in which the heparin binding sites of the two proteins are aligned, but there is a nonproductive engagement of the RCL in thrombin's active site; and another that is a productive Michaelis complex, but is unable to be bridged by heparin. We also observed that the formation of the productive Michaelis complex was associated with a disruption of the structure of thrombin, in particular, the unfolding of the heparin-binding exosite
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From II. We propose a two-step mechanism of thrombin recognition by PN1 where an initial heparin bridged complex is rapidly formed due to electrostatic attraction, without the full engagement of the RCL, followed by a rotation of thrombin relative to PN1 to dock the RCL and fully engage recognition exosites. Formation of the second complex results in the dissociation of heparin from thrombin prior to the translocation of thrombin to form the final inhibitory complex. The final PN1-thrombin complex remains bound to the cell surface through the persistently tight interaction between PN1 and GAGs to promote internalization and cell signaling.
METHODS

Protein production and purification
Catalytically inactive S195A thrombin was the kind gift of Charles T. Esmon, and was produced as described previously 12 . For generating protease nexin-1, full-length cDNA of the beta isoform of PN1, starting at Ser20 (NM_006216, after signal peptide), was cloned into pET19b between NdeI and XhoI site (XhoI site in the PN1 gene was mutated out without changing the amino acid sequence prior to cloning).
The insert was confirmed by DNA sequencing. Bacteria strain Rossetta DE3 pLysS was used for protein expression. Briefly, cells were grown at 37°C until mid-log phase followed by IPTG induction at 25°C overnight. Cells were harvested the next day and resuspended in Tris-buffered saline with Complete protease inhibitor (Roche, EDTA-free). After sonication, cell pellets were separated by centrifugation and the supernatant was loaded onto a 5ml Ni-NTA column (GE Healthcare). Subsequent heparin-Sepharose and S-75 gel filtration chromatography resulted in PN1 of greater than 99% purity. 
Crystallization, data collection and refinement
The PN1-heparin complex was formed by mixing recombinant PN1 at 7.8mg/ml with 2.5-fold molar excess of 10mer heparin (Iduron, Manchester, UK) in a buffer containing 20mM TrisHCl, pH7.4, 100mM NaCl, 5mM EDTA, 1mM DTT.
Diffraction quality crystals were obtained from hanging drop plates with a 1:1 ratio of protein and 25mM sodium acetate buffer, pH4.8, 13% PEG3350 and 200mM ammonium sulphate. Crystals were cryoprotected in 25mM sodium acetate buffer, pH4.8, 13% PEG3350, 0.2M ammonium sulfate, 10μM 10mer heparin, with 25% glycerol. The PN1-thrombin complex was formed by mixing PN1 and S195A thrombin in a 1:1 molar ratio at low concentration, followed by dialysis into 20mM
TrisHCl pH7.4, 50mM NaCl. The complex was then concentrated to 4 mg/ml before setting up crystallization trials. Crystals appeared within a week in 140mM calcium acetate and 13% PEG3350, and were cryoprotected in 140mM calcium acetate, 20% 
RESULTS
Overall structure of heparin-bound PN1
Two copies of PN1 were found in the asymmetric unit (A and B, supplemental Figure   1 ). The overall fold is identical for the two monomers, with a Cα RMSD of 0.88Å, for 361 residues. However, the structures diverged significantly from one another in the conformation of four segments: 97-102, comprising the loop between helix E and strand 3A; 120-161, comprising strand 1A, helix F and the loop following helix F; 309-314, comprising the loop preceding strand 5A; and 341-349, corresponding to the C-terminal portion of the RCL (supplemental Figures 1B and C) . The 120-161 region appears to shift as a single rigid body, while the other changes are plastic. All of the apparent conformational differences can be accounted for by differences in crystal contacts for molecules A and B, and reflect regions of inherent mobility in the serpin structure. Monomer B was chosen as the representative native structure of PN1 since it was the most fully traced in electron density (370 vs. 362 of the 379 residues), and since it matched more closely the structures of PN1 bound to thrombin (discussed later). The model is complete, with the exception of the inherently flexible Nterminus (residues 1-3) and the N-terminal portion of the RCL (335-340, corresponding to P12-P7, using the traditional substrate nomenclature 22 ).
The structure of native PN1 is unsurprisingly similar to that of the archetypal serpin α1-antitrypsin 23 (α1AT), comprised of the same secondary structural elements (9 helices and 3 β-sheets) arranged in a similar manner to make the typical serpin fold ( Figure 1A ). However, as reflected in a Cα RMSD of 2.45Å, PN1 deviates from the structure of α1AT (1QLP) significantly in certain features, in particular, in the orientation of the helices (supplemental Figure 2A) . PN1 is most similar in sequence . However, in spite of the high affinity of PN1 for heparin 28 and the fact that crystals do not form in the absence of heparin, we could only observe weak density for a single disaccharide unit (supplemental Figure 4) . The reason for this is likely to be the juxtaposition of the heparin binding regions of the two monomers within the crystal. Indeed, we chose the composition of our asymmetric unit (supplemental Figure 1A ) based on the intimate nature of the dimer contact (1817Å 2 ). However, an alternative asymmetric unit can be selected that juxtaposes the two heparin binding sites with no apparent intermolecular crystallographic contact ( Figure 2A ). The lack of intermolecular contact is consistent with the charge repulsion between these regions (helix D), and one would expect that in the absence of bound heparin such a repulsive interface would preclude crystallization. The symmetry of the sulfation pattern of heparin allows it to bind the two monomers in an essentially identical fashion if it were to lie along the two-fold axis (supplemental Figure 5A and Figure   2B ). This binding mode corresponds well with the disaccharide unit placed into weak electron density, and may indeed be the favored binding mode within the crystal lattice. However, there is good reason to believe that this mode represents only one of several heparin orientations available to PN1. Indeed, the observed/proposed orientation of heparin shown in Figure 2B would be unlikely to support bridging of thrombin (consistent with the structures described in the following section, supplemental Figure 5B ). In addition, the lack of electron density for the sulfate moieties of heparin and for the Lys side chains of helix D suggest multiple heparin binding modes of similar affinity for PN1. Moreover, the extended crystal packing is permissive of free rotation of the 10mer heparin between the heparin binding sites at the dimer interface.
Two distinct PN1-thrombin complexes
In addition to the structure described above, we also solved the crystal structure of PN1 bound to S195A thrombin to determine the molecular basis of recognition. We found two complexes in the asymmetric unit with distinct orientations of thrombin on PN1 ( Figure 3 ). In the first complex, thrombin is oriented towards the front of PN1, aligning thrombin's heparin binding site (exosite II, indicated) with helix D of PN1
( Figure 3A ). In the second complex, thrombin is rotated ~130° relative to its position in complex 1, so that exosite II is no longer in alignment with helix D of PN1 ( Figure   3B ). Indeed, the position of exosite II in the second complex would preclude simultaneous binding of heparin to both PN1 and thrombin (supplemental Figure 6 ).
Both complexes engage the RCL in the active site cleft, including the insertion of the P1 Arg into the S1 pocket, but only complex 2 engages the RCL in a manner that would be permissive of proteolytic cleavage of the P1-P1′ bond ( Figure 4 ). Thus, we surprisingly observe two complexes that are each at once competent and deficientcomplex 1 is easily bridged by a linear heparin molecule, but has failed to productively engage thrombin's active site; while complex 2 has correctly engaged the RCL of PN1 into the catalytic site of thrombin, but is unable to be bridged by heparin.
Active site interactions
For serpin-protease Michaelis complexes it is generally considered that contacts involving P4-P3′ constitute active site interactions, and those which involve other regions are defined as exosite interactions 29 . The active site interactions for the two PN1-thrombin complexes are clearly defined by electron density (supplemental Figure 7 ), but are unusual in some aspects. In complex 1 ( Figure 3A ), the RCL of PN1 has adopted a helical conformation from residues 338-344 (P9-P3). This conformation is not seen in either of the two copies of native PN1 discussed above, and is therefore likely to have been induced by its interaction with thrombin. This conformation allows the P4 Leu side chain to interact with the S4 pocket on thrombin, however, no other RCL-active site interactions are normal. As mentioned above, complex 1 has engaged the active site, but in a non-productive manner, meaning that the P1 residue is partially buried in the S1 pocket, but does not dock in the manner observed for other thrombin substrates or inhibitors (Figure 4) . Importantly, the P1′
Ser residue is not in its canonical position, instead running below the protruding Glu192 side chain ( Figure 4B ), and away from the oxyanion hole ( Figure 4A ). The RCL of complex 2 engages the P1-P1′ bond in the canonical, productive fashion, but little else about the active site interaction is normal. In particular, the P4 side chain is seen pointing away from thrombin, and the S4 pocket appears to interact instead with the P3 residue, although no density for the P3 Ile side chain is observed. On the other hand, the P′ region makes extensive contacts up to the P5′ residue.
Exosite interactions
In spite of the similar amount of total buried surface area for the two complexes 
Conformational disorder in exosite II
Although the two thrombins in complex with PN1 are similar in overall conformation (Cα RMSD of 0.75Å for 246 residues), thrombin in the second complex is remarkably disordered. This is manifested by poor electron density and high B- For
DISCUSSION
In this study we set out to determine how PN1 recognizes heparin-like GAGs and its target protease thrombin by solving crystal structures of the complexes. These two interactions govern PN1 activity by localizing thrombin to cell surfaces and by conferring exquisite specificity for thrombin. Our structures reveal a normal serpin architecture, but with unusual features particular to the requirement of PN1 to bind to cell-surface GAGs during each stage of its life-cycle.
We were unable to obtain crystals of native PN1 in the absence of heparin. This is perhaps unsurprising due to the highly basic nature of PN1 (theoretical pI is 9.4 and net charge of +10, for the β-isoform without glycosylation) 33 . However, in the presence of a 10-monosaccharide unit heparin chain PN1 crystallized readily and its structure was solved to 2.35Å. Although the crystals were grown in the presence of heparin, we conclude that the resulting structure represents that of physiologically relevant native PN1, since in biology PN1 is always tightly bound to GAGs on cell surfaces.
The lack of electron density for heparin and for the Lys side chains along helix D suggests at least two heparin binding modes. Heparin is a helical rod-like molecule due to its extreme negative charge density, and although it is not strictly symmetrical, the placement of its charges is nearly equivalent on its two faces 34 . This means that heparin can bind most proteins with similar affinities independent of direction (nonreducing end to reducing end) and of register. Because of this, heparin is often found 'sandwiched' between two molecules, mediating dimerization
31
, and is notoriously difficult to model into electron density. However, it is normally possible to observe
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From important sulfate moieties and interacting side chains. Here we find two heparin binding helices juxtaposed with nothing to limit the rotation of heparin along its long and short axes. The fact that we observed no strong density for the sulfate groups of heparin suggests that it is not binding in a prescribed manner and is likely to sample multiple orientations relative to helix D. Placement of heparin along the two-fold axis, as shown in supplemental Figure 5A , nicely aligns the D helices and the Lys side chains with heparin, but in an orientation incapable of bridging thrombin ( Figure 2B and supplemental Figure 5B ). It is thus clear that heparin can rotate to some extent across the face of helix D, while maintaining high affinity, at least within the crystal lattice. A 41° rotation from the placement of heparin along the two-fold crystallographic axis would be sufficient to bridge PN1 to thrombin from complex 1, as shown in Supplemental Figure 5B . The pivot point corresponds nicely to the weak density observed for the disaccharide in the middle of the D-helix.
Previous crystal structures of serpin-protease Michaelis complexes contained either a single complex or two identical complexes in the asymmetric unit. This makes interpretation easy, since the resulting structure is assumed to represent the recognition complex in solution. In the low-resolution structure of the AT-Xa Michaelis complex 35 , two identical copies were found in the asymmetric unit, supporting the conclusion that a single set of interactions defines serpin-protease Michaelis complexes. In a counter example, two very different structures of the ATthrombin complex have been described 12, 36 , indicating that there may be some plasticity in the protein-protein contacts. In a single crystal of PN1 and S195A thrombin we observe two very different and unusual complexes: one is nonproductive due to the misalignment of the P1′ residue, but permits bridging by a linear heparin chain; the other is poised for proteolytic attack of the P1-P1′ bond, but the position and conformation of thrombin would not permit heparin bridging. We are thus faced with the conundrum of deciding which of the two complexes is relevant to the recognition of thrombin by PN1, and thus which explains the exceedingly fast rate of thrombin inhibition by PN1 in the presence of GAGs. However, since both properties are necessary (heparin bridging and proper P1-P1′ engagement), it is possible that they each represent a separate state on the pathway of inhibition. As mentioned above, PN1 is resident on cell-surface GAGs, and it is therefore reasonable to conclude that GAGs will always participate in approximating PN1 and thrombin. Due to the rod-like nature of heparin, formation of the initial bridged complex requires the two heparin binding sites to be aligned. Additional electrostatic complementarity will orient thrombin for docking to the 'top' of PN1 to aid in rapid formation and stabilization of the bridged complex. Accordingly, the region surrounding and including the RCL of PN1 presents a highly basic surface ( Figure 1C ) to the highly negatively charged active site of thrombin ( Figure 4B ). Thus, the driving force for formation of the bridged complex will be electrostatics, initiated by the simultaneous binding of thrombin to the GAG on which PN1 is already resident, followed linear diffusion along the GAG to engage the P1 Arg and Arg269 with the negatively charged active site cleft of thrombin, including the S1 pocket and Glu192. Once this has occurred, thrombin can rotate to fully engage the P1 Arg residue and Arg269, the P′ side of the RCL, and further exosite residues, to form the productive Michaelis complex. Although we do not know which of the two observed complexes is more stable, we can safely conclude that both are likely to be populated in solution for two reasons: 1) we observe both in the crystal structure, and crystal contacts stabilize a We have recently shown that thrombin in its final complex with serpins is functionally deficient with respect to exosite II binding, and that the observed loss of affinity for heparin and other exosite II ligands was due to the conformational disordering of the protease 32 . Surprisingly, the thrombin molecule in the second complex with PN1 was poorly ordered, with several residues lacking density and with highly elevated B-factors. While the effect was global, disorder was particularly evident in the regions that make up exosite II. It is possible to argue that the observed disorder is due to poor crystal packing or some component of the crystallization solution, or perhaps an inadvertent destabilizing mutation. However, we have solved several structures using this thrombin preparation, including three serpin Michaelis complexes, and none showed any conformational disruption. Indeed, we have an internal control in complex 1 that demonstrates a normal stable fold for this thrombin
under these specific conditions. The disordering of thrombin in complex 2 is even more surprising, since occupancy of the active site by substrate or inhibitor is know to stabilize and order thrombin 39 , but here an opposite effect is observed.
Furthermore, our recent NMR study 39 showed that exosite II was insensitive to ligation and was found to be stably formed even in the apo state. It is therefore necessary to conclude that something has happened to thrombin in complex 2 to destabilize thrombin and its exosite II, and that the structural perturbation is caused by the productive engagement of PN1. Such a mechanism makes functional sense, since disengagement of heparin from thrombin should precede translocation of thrombin during formation of the final complex, particularly since PN1 retains high affinity for heparin throughout the process. However, although there is some precedence for allosteric linkage between the active site and exosites of thrombin 40,41 , we cannot discern from the structure the cause of the apparent allosteric disordering of thrombin by PN1. Figure 6 A B
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